About
Technology
Issues
FAQ
Links
Official Page
Activity of docetaxel (D) and new generation hormonotherapies (NGH) in patients with metastatic castrate-resistant prostate cancer (mCRPC) following front line cabazitaxel (C).
site/software ©
exaly
; All materials licenced under
CC by-SA
.